[go: up one dir, main page]

MX2018001435A - Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. - Google Patents

Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.

Info

Publication number
MX2018001435A
MX2018001435A MX2018001435A MX2018001435A MX2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A MX 2018001435 A MX2018001435 A MX 2018001435A
Authority
MX
Mexico
Prior art keywords
lennox
fenfluramine
syndrome
treatment methods
gastaut syndrome
Prior art date
Application number
MX2018001435A
Other languages
English (en)
Other versions
MX389927B (es
Inventor
J Farr Stephen
S Galer Bradley
Original Assignee
Zogenix International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58101064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018001435(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zogenix International Ltd filed Critical Zogenix International Ltd
Publication of MX2018001435A publication Critical patent/MX2018001435A/es
Publication of MX389927B publication Critical patent/MX389927B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paper (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método de tratamiento y/o prevención de síntomas del síndrome de Lennox-Gastaut (LGS) también conocido como Síndrome de Lennox en un paciente, tal como un paciente previamente diagnosticado con el Síndrome de Lennox, mediante la administración de una dosis efectiva de fenfluramina o sus sales farmacéuticamente aceptables a dicho paciente. Los pacientes con Síndrome de Lennox son tratados con una dosis preferida de menos de aproximadamente 2.0 a aproximadamente 0.01 mg / kg / día.
MX2018001435A 2015-08-24 2016-08-24 Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. MX389927B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209090P 2015-08-24 2015-08-24
PCT/US2016/048470 WO2017035267A1 (en) 2015-08-24 2016-08-24 Methods of treating lennox-gastaut syndrome using fenfluramine

Publications (2)

Publication Number Publication Date
MX2018001435A true MX2018001435A (es) 2018-04-20
MX389927B MX389927B (es) 2025-03-20

Family

ID=58101064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001435A MX389927B (es) 2015-08-24 2016-08-24 Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.

Country Status (22)

Country Link
US (4) US20170056344A1 (es)
EP (2) EP4397372A3 (es)
JP (1) JP6895949B2 (es)
KR (3) KR102615486B1 (es)
CN (3) CN108135865A (es)
AU (1) AU2016312526B2 (es)
BR (1) BR112018002046A2 (es)
CA (1) CA2993665C (es)
DK (1) DK3340971T3 (es)
ES (1) ES2979034T3 (es)
FI (1) FI3340971T3 (es)
HR (1) HRP20240508T1 (es)
HU (1) HUE066912T2 (es)
IL (1) IL257276B (es)
LT (1) LT3340971T (es)
MX (1) MX389927B (es)
PL (1) PL3340971T3 (es)
PT (1) PT3340971T (es)
RU (1) RU2740919C2 (es)
SI (1) SI3340971T1 (es)
WO (1) WO2017035267A1 (es)
ZA (1) ZA201800499B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109262888A (zh) 2010-11-12 2019-01-25 尼亚加拉瓶业有限公司 塑料预成型体和由该预成型体制成的瓶或容器
US10647465B2 (en) 2010-11-12 2020-05-12 Niagara Bottling, Llc Perform extended finish for processing light weight ecologically beneficial bottles
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT3393655T (pt) 2015-12-22 2021-02-23 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
ES3029536T3 (en) 2016-08-24 2025-06-24 Zogenix International Ltd Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
BR112019023483A2 (pt) * 2017-05-09 2020-06-30 Zogenix International Limited composição farmacêutica para uso no tratamento, na prevenção e/ou no melhoramento dos sintomas da síndrome de doose, e, kit para tratar, prevenir e/ou melhorar um sintoma da síndrome de doose
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
WO2019216919A1 (en) * 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
EP3820459A1 (en) * 2018-07-10 2021-05-19 Zogenix International Limited Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension
US11597556B2 (en) 2018-07-30 2023-03-07 Niagara Bottling, Llc Container preform with tamper evidence finish portion
WO2020105005A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
JP2022521446A (ja) * 2019-02-25 2022-04-07 ゾゲニクス インターナショナル リミテッド 発作制御を改善するための製剤
WO2021053389A1 (en) * 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
US20210299064A1 (en) * 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
CN101257889A (zh) * 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
GB0515090D0 (en) * 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
CA2741644C (en) * 2008-10-30 2013-05-07 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US20110212171A1 (en) * 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP2560634A1 (en) * 2010-04-23 2013-02-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
LT3035926T (lt) * 2013-08-19 2020-11-25 The Regents Of The University Of California Junginiai ir būdai, skirti epileptinio sutrikimo gydymui
RU2704749C2 (ru) 2014-09-29 2019-10-30 Зодженикс Интернэшнл Лимитед Система управления для управления распределением лекарственных продуктов

Also Published As

Publication number Publication date
KR20230005426A (ko) 2023-01-09
JP6895949B2 (ja) 2021-06-30
CN115350168A (zh) 2022-11-18
HRP20240508T1 (hr) 2024-07-05
PT3340971T (pt) 2024-06-05
IL257276B (en) 2022-06-01
AU2016312526B2 (en) 2021-09-09
EP3340971A4 (en) 2019-05-01
EP4397372A3 (en) 2024-09-11
EP3340971A1 (en) 2018-07-04
RU2740919C2 (ru) 2021-01-21
FI3340971T3 (fi) 2024-06-10
IL257276A (en) 2018-03-29
US20200253895A1 (en) 2020-08-13
CN115192575A (zh) 2022-10-18
EP3340971B1 (en) 2024-03-13
EP4397372A2 (en) 2024-07-10
US20170056344A1 (en) 2017-03-02
KR20180054584A (ko) 2018-05-24
US20240238222A1 (en) 2024-07-18
BR112018002046A2 (pt) 2018-09-18
ZA201800499B (en) 2018-12-19
MX389927B (es) 2025-03-20
RU2018108202A3 (es) 2020-01-20
ES2979034T3 (es) 2024-09-23
CA2993665A1 (en) 2017-03-02
PL3340971T3 (pl) 2024-07-15
HUE066912T2 (hu) 2024-09-28
WO2017035267A1 (en) 2017-03-02
AU2016312526A1 (en) 2018-02-22
KR102481631B1 (ko) 2022-12-27
RU2018108202A (ru) 2019-09-26
DK3340971T3 (da) 2024-05-27
CN108135865A (zh) 2018-06-08
SI3340971T1 (sl) 2024-05-31
CA2993665C (en) 2023-03-07
KR102615486B1 (ko) 2023-12-19
JP2018525418A (ja) 2018-09-06
KR20220025927A (ko) 2022-03-03
LT3340971T (lt) 2024-04-25
US20240245631A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MY189601A (en) Treatment of beta-thalassemia using actrii ligand traps
SG10201902664RA (en) Combination therapy for treating cancer
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2018002906A (es) Metodos de tratamiento de trastornos del desarrollo con pipradrol.
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX366497B (es) Cepas de bacteriófagos capaces de producir una infección lítica en una cepa de escherichia coli adherente-invasiva y su uso para el tratamiento de enfermedades inflamatorias intestinales.
EP4570314A3 (en) Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020007462A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
BR112016029437A2 (pt) métodos para tratamento e prevenção de doenças de instabilidade vascular
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019004200A (es) Terapia de combinacion.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.